Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
Agenus (NASDAQ: AGEN) has announced its plan to release third quarter 2021 financial results on November 9, 2021, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus (NASDAQ: AGEN) has announced its plan to release third quarter 2021 financial results on November 9, 2021, before the market opens. The company will also hold a conference call at 8:30 a.m. ET on the same day to discuss these results and provide a corporate update. Agenus, based in Lexington, MA, focuses on immuno-oncology therapies aimed at engaging the body’s immune system to combat cancer. Investors can access the live webcast and replay via the company’s website.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was -5.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET
LEXINGTON, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its third quarter 2021 financial results before the market opens on Tuesday, November 9, 2021. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update.
Conference Call
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International).
Conference ID number: 8585893.
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gsbikqz2.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its affiliate MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Inc.
Divya Vasudevan, PhD
781-674-4571
divya.vasudevan@agenusbio.com
Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.